Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Gains from Investment Securities (2016 - 2025)

Aptevo Therapeutics' Gains from Investment Securities history spans 11 years, with the latest figure at $2850.0 for Q1 2025.

  • For Q1 2025, Gains from Investment Securities changed N/A year-over-year to $2850.0; the TTM value through Mar 2025 reached $2850.0, changed N/A, while the annual FY2024 figure was $2.0, 99.43% down from the prior year.
  • Gains from Investment Securities for Q1 2025 was $2850.0 at Aptevo Therapeutics, up from $2.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $400000.0 in Q2 2022 and bottomed at $2.0 in Q4 2024.
  • The 5-year median for Gains from Investment Securities is $80605.0 (2021), against an average of $155255.3.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 10854.11% in 2022 before it plummeted 99.9% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $334412.0 in 2021, then rose by 8.93% to $364266.0 in 2022, then tumbled by 99.9% to $352.0 in 2023, then crashed by 99.43% to $2.0 in 2024, then soared by 142400.0% to $2850.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Gains from Investment Securities are $2850.0 (Q1 2025), $2.0 (Q4 2024), and $352.0 (Q4 2023).